Increased interleukin-10 serum levels in patients with solid tumours

In 40 out of 99 patients (40.4%) with solid tumours of different tissue, but the same stage (IV), elevated serum levels of interleukin-10 were observed. The mean levels of the cytokine in patients with malignant melanoma (24.3 ng/ml), pancreatic (6.8 ng/ml) or gastric (6.3 ng/ml) adenocarcinoma were...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 1996-06, Vol.104 (1), p.1-5
Main Authors: Fortis, Claudio, Foppoli, Marco, Gianotti, Luca, Galli, Laura, Citterio, Giovanni, Consogno, Giuseppe, Gentilini, Oreste, Braga, Marco
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Female
Host-tumor relations. Immunology. Biological markers
Humans
Immune surveillance
Immunological escape
Interleukin-10
Interleukin-10 - blood
Macrophages
Male
Medical sciences
Middle Aged
Neoplasm Staging
Neoplasms - blood
Reference Values
Solid tumour: T lymphocytes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 40 out of 99 patients (40.4%) with solid tumours of different tissue, but the same stage (IV), elevated serum levels of interleukin-10 were observed. The mean levels of the cytokine in patients with malignant melanoma (24.3 ng/ml), pancreatic (6.8 ng/ml) or gastric (6.3 ng/ml) adenocarcinoma were significantly higher than in healthy subjects (3.4 ng/ml) or in patients with uterine fibroma (1.7 ng/ml). Patients with colon (6.8 ng/ml) and renal (5.7 ng/ml) carcinoma had similar values of interleukin-10 but did not significantly differ from controls. Interleukin-10 is known to suppress the functions of both T lymphocytes and macrophages, working as a general dampener of the immune and inflammatory responses. The observation of increased circulating levels of interleukin-10 in cancer patients may have important implications for future investigations, immunological monitoring and therapeutic intervention on neoplastic patients, and suggests a mechanism for tumour cells escaping from immune surveillance.
ISSN:0304-3835
1872-7980
DOI:10.1016/0304-3835(96)04213-9